JP2024525610A5 - - Google Patents
Info
- Publication number
- JP2024525610A5 JP2024525610A5 JP2024500477A JP2024500477A JP2024525610A5 JP 2024525610 A5 JP2024525610 A5 JP 2024525610A5 JP 2024500477 A JP2024500477 A JP 2024500477A JP 2024500477 A JP2024500477 A JP 2024500477A JP 2024525610 A5 JP2024525610 A5 JP 2024525610A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- oligonucleotide
- complex according
- optionally
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163219977P | 2021-07-09 | 2021-07-09 | |
| US63/219,977 | 2021-07-09 | ||
| PCT/US2022/073528 WO2023283614A2 (en) | 2021-07-09 | 2022-07-08 | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525610A JP2024525610A (ja) | 2024-07-12 |
| JP2024525610A5 true JP2024525610A5 (enExample) | 2025-07-17 |
Family
ID=84802085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500477A Pending JP2024525610A (ja) | 2021-07-09 | 2022-07-08 | 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240209119A1 (enExample) |
| EP (1) | EP4367247A4 (enExample) |
| JP (1) | JP2024525610A (enExample) |
| KR (1) | KR20240035823A (enExample) |
| CN (1) | CN118510898A (enExample) |
| AU (1) | AU2022307934A1 (enExample) |
| CA (1) | CA3226298A1 (enExample) |
| IL (1) | IL309909A (enExample) |
| MX (1) | MX2024000490A (enExample) |
| WO (1) | WO2023283614A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
| CN118546927B (zh) * | 2024-05-29 | 2025-02-25 | 广东省农业科学院动物科学研究所 | 一种靶向敲低鸡SRSF2基因表达的siRNA及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2639852T3 (es) * | 2007-10-26 | 2017-10-30 | Academisch Ziekenhuis Leiden | Medios y métodos para contrarrestar los trastornos musculares |
| CA3108282A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| MX2023000984A (es) * | 2020-07-23 | 2023-05-03 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias. |
-
2022
- 2022-07-08 KR KR1020247004286A patent/KR20240035823A/ko active Pending
- 2022-07-08 CA CA3226298A patent/CA3226298A1/en active Pending
- 2022-07-08 AU AU2022307934A patent/AU2022307934A1/en active Pending
- 2022-07-08 MX MX2024000490A patent/MX2024000490A/es unknown
- 2022-07-08 WO PCT/US2022/073528 patent/WO2023283614A2/en not_active Ceased
- 2022-07-08 US US18/577,462 patent/US20240209119A1/en active Pending
- 2022-07-08 JP JP2024500477A patent/JP2024525610A/ja active Pending
- 2022-07-08 IL IL309909A patent/IL309909A/en unknown
- 2022-07-08 EP EP22838586.0A patent/EP4367247A4/en active Pending
- 2022-07-08 CN CN202280060816.6A patent/CN118510898A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024525610A5 (enExample) | ||
| JP2024527362A5 (enExample) | ||
| JP2024525611A5 (enExample) | ||
| JP2024525613A5 (enExample) | ||
| JP2024525612A5 (enExample) | ||
| IL309909A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309937A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| JP2023510350A5 (enExample) | ||
| IL309912A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309935A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309911A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| JP2023535073A5 (enExample) | ||
| US20240325558A1 (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| US11771776B2 (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| JP2023509793A5 (enExample) | ||
| US20230285586A1 (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| US20240117356A1 (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| US20230088865A1 (en) | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy | |
| JP2024540199A5 (enExample) | ||
| US20230103793A1 (en) | Anti-transferrin receptor (tfr) antibody and uses thereof | |
| IL309936A (en) | Muscle targeting complexes and formulations for the treatment of dystrophinopathy | |
| US20250360223A1 (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| JP2024524222A5 (enExample) | ||
| IL316143A (en) | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy | |
| JP2024540199A (ja) | ジストロフィノパチーを処置するための筋標的化複合体 |